PBPK Modeling & Simulation

Reasons to Attend Certara’s CADD, PK/PD, and PBPK Modeling Courses

Suzanne Minton

As the manager of scientific communication for Certara, part of my job is to educate new and existing clients on the ways they can maximize their utilization of Certara’s software and consulting services. Therefore, it was important for me, early on, to experience our training solutions to better understand our clients’ perspectives. At Certara, we […]

Read More
Topics: PBPK Modeling & Simulation, PK/PD Modeling & Simulation

Solving Molecular Discovery Problems with CoMFA over the Years

Richard Cramer

Nearly half of drug candidates fail because of inadequate safety in pre-clinical testing, representing an expensive loss of investment and lost opportunity. Often, drugs are found to cause toxicity through off-target activity. Therefore, understanding how drugs interact with their target receptors, and minimizing off-target activity is crucial to developing effective medications. Over my career, I’ve […]

Read More
Topics: Uncategorized

Commonly Held Myths About the FDA’s CDISC Mandate

Peter Schaefer

Have you heard the FDA will require electronic submissions that use CDISC standardized study data? In my work at Certara, I’ve noticed there’s a lot of confusion, and even significant apprehension, surrounding this issue. To combat the misconceptions about what these regulations will mean for drug developers, I’ve compiled a list of common questions (and […]

Read More
Topics: PK/PD Modeling & Simulation

Synthetic Chemistry + CADD = Muse Invent

Brian Masek

Welcome! We’re excited to launch Certara’s blog. This gives us a chance to comment on important news and topics in the rapidly changing world of drug development. Our blog will offer more than one contributor to ensure you get multiple perspectives on the issues impacting us all. We hope that you’ll share your comments about our solutions […]

Read More
Topics: Uncategorized

How PBPK Modeling Will Make Drugs Safer, Cheaper, and More Effective

Daniel Weiner

Historically, drugs have been selected using various methods (eg, biological and chemical screens). Candidate drugs were often pushed into the clinic with only a rudimentary understanding of the link between drug exposure and resultant effect(s). As a consequence, drug development has been inefficient by relying on trial and error at the clinical stage, not to […]

Read More
Topics: PBPK Modeling & Simulation